StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $187M in Q3 2026, up 6.3% from a year earlier.

Latest, Q3 2026
187
Period ended Sep 30, 2026
Change on a year earlier
+6.3%
176 in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Sandostatin Group | Established brands | Carcinoid tumors, acromegaly | 187 | 6 | 124 | – 2 | – 3 | 311 | 3 | 3”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 2026187+6.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026177-5.3%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026162-17.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025169-12.0%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025176-5.9%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 20251870.0%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025197-17.6%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024192-3.5%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024187-14.2%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024187-7.9%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024239+14.4%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023199-2.0%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023218+14.7%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023203-1.9%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023209+4.5%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022203-2.4%Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-sandostatin-group-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.